Yes-associated protein (YAP) is a downstream target of the Hippo pathway and has been found to be oncogenic driving many cancers into developing metastatic phenotypes leading to poor survival outcomes. This study investigated if YAP expression is associated with drug resistance in two non-small cell lung cancer (NSCLC) lines (HCC827 and H1975) generated to become resistant to the EGFR tyrosine ...

Manuscript title A Significance of MMP-1 in EGFR-TKI Resistant Lung Adenocarcinoma: A Potential of Therapeutic Target Running title: A Role of MMP-1 in EGFR-TKI Resistant Lung Adenocarcinoma Authors: Ryoko Saito, [email protected] Yasuhiro Miki, [email protected] Naoya Ishida, [email protected] Chihiro Inoue, [email protected] Masayuki Kobayashi...

Selective tyrosine kinase inhibitor (TKI) targeting KIT and PDGFRA is the frontline therapy for metastatic and unresectable GIST patients. Some initially responsive patients experience tumor progress because of secondary drug resistance, and some cases can develop heterogeneous differentiation. Here we report a rare case of recurrent retroperitoneal extra-GIST with rhabdomyosarcomatous and chon...

Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer. However, the responders acquire resistance almost without exception. We recently reported that hepatocyte growth factor (HGF) induces EGFR-TKI resistance by activatingMET that restores downstreammitogen activated protein kinase (...

Purpose: MicroRNA-630 plays dual roles in apoptosis and drug resistance in human cancers. However, the role of miR-630 in resistance to tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma remains to be elucidated. Methods: Manipulation of miR-630 and its targeted gene YAP1 and/or combination of inhibitor treatments was performed to explore whether low miR-630 could confer TKI resistance du...

BACKGROUND Readministering a second epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with acquired resistance to an initial EGFR TKI is a common treatment strategy. However, the prognostic factors for the second EGFR TKI are still uncertain. PATIENTS AND METHODS In this retrospective study, we enrolled patients with stage IV lung ade...

Teknologi Informasi sudah dimanfaatkan oleh hampir seluruh instansi baik swasta maupun pemerintah, begitu juga dilingkungan Dinas Tenaga Kerja dan Transmigrasi (Disnakertrans). Salah satu tugas dari Disnakertrans adalah dengan mengelola Indonesia (TKI) mulai Administrasi, pelatihan, serta penempatan TKI di luar negeri. Penerapan Sistem merupakan bagian yang terpenting bagi untuk meningkatkan pe...

Over the last decades, billions have been spent and huge efforts have been taken in basic and clinical cancer research [CA Cancer J Clin63:11-30]. About a decade ago, the arms race between drugs and cancer cells reached a new level by introduction of tyrosine kinase inhibitors (TKI) into pharmacological anti-cancer therapy. According to their molecular mechanism of action, TKI in contrast to so...

Despite initial high response rate to tyrosine kinase inhibitor (TKI) treatment, non-small cell lung cancer (NSCLC) patients whose tumors harbour activating mutation in their epidermal growth factor receptors (EGFR) gene invariably develop TKI resistance. Secondary mutation T790M in EGFR and MET amplification were found in over 50% tumors. However, there are up to 30% of cases, whose mechanisms...

The epidermal growth factor receptor (EGFR) is a well-characterized oncogene that is frequently activated by somatic kinase domain mutations in non-small cell lung cancer (NSCLC). EGFR TKIs are effective therapies for NSCLC patients whose tumors harbor an EGFR activating mutation. However, EGFR TKI treatment is not curative in patients because of both primary and secondary treatment resistance....